Globeimmune Inc banner

Intrinsic Value

GBIM latest financial reports are more than 6 years old.
GBIM doesn't have a meaningful market cap.
Not Available for GBIM

There is not enough data to reliably calculate the intrinsic value for Globeimmune Inc.

Do our valuations actually work? See backtest results .

Alternatives to GBIM

Fundamental Analysis

What Globeimmune Does

Biotechnology Health Care

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production.

Headquarters
United States of America US
Employees
3
IPO date
Jul 2, 2014
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Globeimmune Inc

Wall St Price Targets

Capital Returns

Buyback Yield
LOCKED
Debt Paydown Yield
LOCKED

Competitive Landscape